Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Avient Corporation (AVNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Avient Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.77 (market cap $29.60B), while Avient Corporation trades at $45.2 (market cap $4.17B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.1× Avient Corporation's market cap, and Avient Corporation pays a 2.42% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | AVNT | |
|---|---|---|
Market Cap | $29.60B | $4.17B |
Sector | Health | Technology |
52-Week High | $491.22 | $45.69 |
52-Week Low | $205.48 | $27.48 |
Enterprise Value | $27.56B | $5.62B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Avient (AVNT) trades at $45.1, down 1.2% today, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings of $0.96 per share, beating estimates, and has consistently exceeded expectations in recent quarters. Revenue remains stable at $3.3 billion, with a net income margin improving to 5.1% in 2026. Analysts maintain a Buy consensus with a $49 price target, reflecting optimism about continued growth and dividend stability.
The stock offers upside potential from earnings momentum and a solid dividend yield, but faces risks from macroeconomic pressures on materials demand and high RSI levels suggesting overbought conditions. Institutional sentiment is positive, with no Sell ratings, though investors should monitor debt levels and competitive dynamics in the chemical sector for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →
